Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial.
Abtract: The SWOG S1801 trial investigated the role of pembrolizumab, an anti-PD1 immune checkpoint inhibitor, in the perioperative setting of stage III or IV melanoma. This phase 2 trial compared two groups: one receiving pembrolizumab both before and after surgery (neoadjuvant-adjuvant), and anoth...
| Main Authors: | , |
|---|---|
| 格式: | 文件 |
| 语言: | English |
| 出版: |
Elsevier
2024-07-01
|
| 丛编: | Translational Oncology |
| 主题: | |
| 在线阅读: | http://www.sciencedirect.com/science/article/pii/S193652332400086X |